Glycolipid Disialoganglioside-directed Antibody [EPC]

1085 reported adverse events

Drugs of this class: DINUTUXIMAB NAXITAMAB

These side effects are most commonly reported by patients taking drugs of the Glycolipid Disialoganglioside-directed Antibody [EPC] class:

# Side effect Count
0 PYREXIA 196
1 PAIN 154
2 OFF LABEL USE 140
3 HYPOTENSION 125
4 ABDOMINAL PAIN 97
5 NEUROBLASTOMA RECURRENT 89
6 VOMITING 81
7 ASPARTATE AMINOTRANSFERASE INCREASED 65
8 ALANINE AMINOTRANSFERASE INCREASED 63
9 HYPOXIA 63
See all common reactions for Glycolipid Disialoganglioside-directed Antibody [EPC]

Drugs of the Glycolipid Disialoganglioside-directed Antibody [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 MALIGNANT CRANIAL NERVE NEOPLASM 18 0.6923
1 NEUROBLASTOMA RECURRENT 89 0.4384
2 RETRO-ORBITAL NEOPLASM 18 0.3396
3 NEUROBLASTOMA 58 0.1514
4 CAPILLARY LEAK SYNDROME 33 0.0159
5 MYELITIS TRANSVERSE 17 0.0121
6 HYPOALBUMINAEMIA 55 0.0071
7 METASTASES TO SPINE 18 0.0054
8 FUNGAEMIA 8 0.0051
9 BONE MARROW TOXICITY 6 0.0051
See all enriched reactions for Glycolipid Disialoganglioside-directed Antibody [EPC]